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ABSTRACT
Objective To assess the cost-effectiveness of dabigatran
etexilate, a new oral anticoagulant, versus warfarin and
other alternatives for the prevention of stroke and
systemic embolism in UK patients with atrial ﬁbrillation
(AF).
Methods A Markov model estimated the cost-
effectiveness of dabigatran etexilate versus warfarin,
aspirin or no therapy. Two patient cohorts with AF
(starting age of <80 and $80 years) were considered
separately, in line with the UK labelled indication.
Modelled outcomes over a lifetime horizon included
clinical events, quality-adjusted life years (QALYs), total
costs and incremental cost-effectiveness ratios (ICERs).
Results Patients treated with dabigatran etexilate
experienced fewer ischaemic strokes (3.74 dabigatran
etexilate vs 3.97 warfarin) and fewer combined
intracranial haemorrhages and haemorrhagic strokes
(0.43 dabigatran etexilate vs 0.99 warfarin) per 100
patient-years. Larger differences were observed
comparing dabigatran etexilate with aspirin or no
therapy. For patients initiating treatment at ages <80
and $80 years, the ICERs for dabigatran etexilate were
£4831 and £7090/QALY gained versus warfarin with
a probability of cost-effectiveness at £20000/QALY
gained of 98% and 63%, respectively. For the patient
cohort starting treatment at ages <80 years, the ICER
versus aspirin was £3457/QALY gained and dabigatran
etexilate was dominant (ie, was less costly and more
effective) compared with no therapy. These results were
robust in sensitivity analyses.
Conclusions This economic evaluation suggests that
the use of dabigatran etexilate as a ﬁrst-line treatment
for the prevention of stroke and systemic embolism is
likely to be cost-effective in eligible UK patients with AF.
INTRODUCTION
Atrial ﬁbrillation (AF), the most common clinically
signiﬁcant cardiac arrhythmia, has an estimated
diagnosed prevalence of about 1.4% in the UK and
is rising.
1 2 Patients with AF have a ﬁvefold
increased risk of stroke compared with those in
sinus rhythm.
3 Stroke events result in substantial
management and follow-up care, and the incurred
costs tend to be higher in stroke patients with AF
than those without.
34Additionally, AF is associ-
ated with an increased risk of non-cranial systemic
embolism (SE).
5 Despite the substantial clinical
risks and economic costs, many patients with AF
receive inadequate stroke prevention treatment
resulting in a rising burden of stroke in patients
with AF in the UK.
23
One of the principal aims of AF treatment is to
avoid thromboembolic events by instituting antith-
rombotic therapy.
3 Vitamin K antagonists such as
warfarin may prevent up to 64% of strokes in
patients with non-valvular AF.
6 However, warfarin
treatment is complex; it has many important inter-
actions with food and drugs, requires frequent
laboratory monitoring of the international normal-
ised ratio (INR), and has potential to cause serious
haemorrhagic events that can be catastrophic.
78
Due to these concerns, many patients in the UK are
under-treated with aspirin or remain untreated.
There is a need, therefore, for safer, more efﬁcacious
and less complex stroke prevention therapy.
39
Dabigatran etexilate (dabigatran) is the ﬁrst new
oral anticoagulant to become available for the
prevention of stroke and SE in patients with AF in
over 50 years.
10 It is a reversible direct thrombin
inhibitor with stable pharmacokinetic and phar-
macodynamic properties and a wide therapeutic
margin.
11 Unlike warfarin, it does not require INR
monitoring or frequent dose adjustments. In the
Randomised Evaluation of Long-Term Anti-
coagulation Therapy (RE-LY) comparative trial, the
150 mg twice daily dose of dabigatran was superior
to warfarin in preventing stroke and SE, and the
110 mg twice daily dose was non-inferior (RR vs
warfarin 0.65, 95% CI 0.52 to 0.81 for dabigatran
150 mg twice daily; RR 0.90, 95% CI 0.74 to 1.10
for dabigatran 110 mg twice daily). Similar rates of
major bleeding occurred with dabigatran 150 mg
twice daily and warfarin (RR vs warfarin 0.93, 95%
CI 0.81 to 1.07), but the 110 mg twice daily dose
had fewer major bleeds (RR vs warfarin 0.80, 95%
CI 0.70 to 0.93). The most important haemorrhagic
complications associated with anticoagulation
therapy (intracranial haemorrhage (ICH) and
haemorrhagic stroke) were signiﬁcantly less likely
with both doses of dabigatran compared with
warfarin.
12 13 Based on the beneﬁts of dabigatran
demonstrated in the RE-LY trial, clinical guidelines
in Europe and North America now include dabiga-
tran as an alternative to warfarin for stroke
prevention in patients with AF.
81 01 4
Besides an assessment of relative efﬁcacy and
safety, adoption of new treatments is also inﬂu-
enced by cost-effectiveness; the decision whether
the added value is worth the added cost. The
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Heart rhythm disorderspresent study used an economic model to systematically assess
the costs and consequences of dabigatran treatment used per its
European indication, in which the 150 mg dose is recommended
for patients under age 80 and the 110 mg dose for those aged 80
and over. The analyses compare dabigatran with warfarin (with
trial-like INR control), aspirin and no treatment. The overall
cost-effectiveness of dabigatran was quantiﬁed as incremental
cost incurred per quality-adjusted year of life (QALY) gained
with dabigatran treatment.
METHODS
Overview
A Markov model was developed to estimate the cost-effectiveness
of dabigatran in eligible patients with AF, which has been described
in detail previously.
15 16 In brief, the model assumed that patients
received dabigatran 150 mg twice daily until age 80 and 110 mg
twice daily thereafter (‘sequential dabigatran’), which reﬂects the
intended clinical use of dabigatran based on the approved European
label.
17 Comparators relevant for the UK setting and evaluated in
the model were warfarin treatment, aspirin monotherapy, and no
treatment. Patients receiving warfarin were assumed to maintain
a level of INR control consistent with that observed in RE-LY
(mean of 64% time in therapeutic range), which compares
favourably with that observed in routine UK practice.
18 19 There-
fore it can be regarded that dabigatran was compared to trial-like
warfarin in the UK setting.
Model structure
The model followed patients with AF through the natural
course of disease in 3-month cycles, included all relevant clinical
outcomes and incorporated health states stratiﬁed by treatment
history, stroke history and disability level.
16 Major clinical
events included in the model were primary and recurrent strokes
(ischaemic (IS) and haemorrhagic (HS)), SE, transient ischaemic
attack (TIA), acute myocardial infarction (AMI), ICH excluding
HS, major extracranial haemorrhage (ECH), minor bleeding and
death. Each event was deﬁned in accordance with clinical deﬁ-
nitions from the RE-LY trial.
12 13 IS, HS and ICH could be
disabling or non-disabling, with disabling events resulting in
permanent functional deﬁcits characterised by modiﬁed Rankin
Score (mRS) for IS, and by Glasgow Outcomes Scale (GOS) for
ICH and HS. All haemorrhagic events could result in discon-
tinuation of current treatment. Patients could also discontinue
for other, possibly non-clinical, reasons. When patients discon-
tinued anticoagulant therapy, they switched to aspirin. Patients
who discontinued aspirin received no further antithrombotic
therapy. A model structure outline is presented in ﬁgure 1.
Model outcomes included number of clinical events normal-
ised to 100 patient-years, QALYs, total and disaggregated costs
(drug, clinical event and follow-up costs) and incremental cost
per QALY gained. QALYs are computed by multiplying the time
a patient survives by a weight representing their quality of life
during that time, with weights ranging from 1 (perfect health)
to 0 (death). Because the consequences of stroke and haemor-
rhage could be life long, the model assumed a lifetime horizon
(up to 100 years of age) in the base case. The model assumed
patients not discontinuing remain adherent to antithrombotic
treatment, and the relative treatment effect remained constant
over time. Patients discontinuing treatment received no further
clinical beneﬁt. Future costs and outcomes were discounted at
3.5% per annum.
The intention was that all aspects of the analysis were
conducted in line with the principles of the National Institute
for Health and Clinical Excellence (NICE) Reference Case
wherever possible.
20 The model implementation used Microsoft
Excel.
Data sources
The primary source of clinical input data was the RE-LY trial,
12 13
and an adaptation of a published mixed treatment comparison
based on a network meta-analysis to synthesise efﬁcacy and
safety data of treatments frequently used in prevention of stroke
and SE in patients with AF.
21
Figure 1 Schematic diagram of the
model structure. Patients in each of the
four treatment groups in the left ﬁgure
proceed through the Markov process
designated by ‘M’. Patients can be in
any of the health states deﬁned by
disability and stroke history (illustrated
in the middle ﬁgure) and by treatment
line (not depicted). Patients begin with
no disability, but some may have prior
history of stroke. All surviving patients
can have any of the events noted by the
square (right diagram) occurring in
a given model cycle, including no event.
Based on these events, patients may
change their health state (eg,
developing stroke history or greater
disability) and treatment regimen. Note
that ‘stroke history’ refers to history of
those events that increase the risk of
subsequent stroke as per the CHADS2
score (ie, ischaemic stroke or TIA).
*150 mg twice daily for patients
<80 years; 110 mg twice daily for patients
$80 years. yMinor bleeds can occur in any
cycle. AMI, acute myocardial infarction; ECH,
extracranial haemorrhage; ICH, intracranial haemorrhage;
TIA, transient ischaemic attack.
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Heart rhythm disordersBaseline characteristics of the patient population in the model
matched those randomised to the RE-LY trial. Patients were
diagnosed with AF plus at least one additional risk factor for
stroke or SE, as deﬁned by the CHADS2 risk stratiﬁcation
scheme, or impaired left ventricular ejection fraction. Patients
had CHADS2 scores ranging from 0 to 6. The mean CHADS2
score in RE-LY was 2.1, with roughly two-thirds of patients
having a CHADS2 score of 2 or higher. At baseline, approxi-
mately 20% of patients had a history of previous stroke or TIA.
As a result, the stroke risk proﬁle of included patients aligns with
that expected to be observed in UK practice.
Patients were assumed not to be receiving any concomitant
anticoagulation medication. The RE-LY population was strati-
ﬁed into those aged <80 years and those aged $80 years using
a post-hoc subgroup analysis. A sensitivity analysis using the
full RE-LY dataset for each dose was also performed.
Utility values for each disability level and utility decrements
due to clinical events were taken from published literature.
22 23
These parameters have been described in detail previously and
are summarised in the online appendix.
16
Table 1 summarises drug, event and follow-up costs used in
this analysis. Drug costs for warfarin and aspirin were £0.04 and
£0.09 per day, respectively, while dabigatran costs were £2.52 per
day.
24 The average annual cost of INR monitoring for warfarin
patients was based on an analysis undertaken by NICE
25 in the
base case, with a plausible range tested in sensitivity analysis
due to regional variation within the UK. Acute management
costs following SE, AMI, TIA and ECH were assessed based on
National Health Service reference costs.
26 Costs for management
of minor bleeds were based on the NICE clinical guideline
for AF.
25 Acute management costs for all other events (IS, ICH
and HS) were calculated from a recent study of AF patient data
from a UK stroke registry, as were costs for long-term manage-
ment of disability resulting from IS, ICH or HS.
27 All cost inputs
were inﬂated to 2010 when necessary.
28
Analysis
The base-case analysis compared ‘sequential’ dabigatran to
trial-like warfarin, that is, in patients initiating treatment
before 80 years of age, who may receive the full treatment
sequence, and in patients starting at or after 80 years of age,
who receive only the 110 mg twice daily dabigatran dose.
Scenario analyses were performed comparing dabigatran with
aspirin and with no treatment. Deterministic sensitivity
analyses were used to identify key determinants of cost effec-
tiveness by varying parameters individually. Finally, probabi-
listic sensitivity analyses (PSAs) assessed the uncertainty
associated with the cost-effectiveness results by performing
5000 simulations for each comparison in which clinical, cost
and utility parameters were simultaneously varied randomly
within their statistical distributions, based on their means and
95% CIs. When 95% CIs were not available, standard errors
were assumed to be 20% of the mean. For the PSAs, baseline
risks of clinical events were assumed to have beta distributions,
while RRs were assumed to be log-normally distributed. Event
costs and utilities were assumed to have gamma and beta
distributions, respectively.
RESULTS
Base-case analyses
Compared with warfarin, patients treated sequentially over
their remaining lifetime with dabigatran experienced fewer total
ICH and HS (0.43 vs 0.99) and IS (3.74 vs 3.97) events per 100
patient-years, but more ECH (3.88 vs 3.57) and AMI (1.27 vs
1.06) events per 100 patient-years. Predicted number of fatal
ICH and HS events was also lower with dabigatran (0.18 vs
0.47), whereas the number of fatal IS events was similar (1.40 vs
1.43). Clinical event differences were found to be somewhat
smaller for IS and larger for ICH and HS in patients initiating
treatment at age 80 or above. In this population, the dabigatran
and warfarin groups experienced similar numbers of IS (4.19 vs
4.13) but total ICH and HS events were more than halved in the
dabigatran-treated group (0.58 vs 1.32).
These differences in clinical event rates resulted in an increase
in QALYs for dabigatran-treated patients versus warfarin (8.06
vs 7.82). This was accompanied by higher lifetime cost per
patient for disease management with dabigatran (£19645 vs
£18474), due to the higher drug costs (35% of total dabigatran
costs vs 17% of total warfarin costs, including INR monitoring).
In both treatment groups, follow-up costs represented the
largest share of costs (47% for dabigatran vs 61% for warfarin),
with the remaining fraction attributed to acute event manage-
ment. In the scenario analyses, aspirin and no treatment
provided fewer QALYs (7.59 and 7.12, respectively) than dabi-
gatran. Aspirin resulted in lower overall costs than dabigatran,
but the higher event rate in the no treatment group resulted in
higher total management costs, despite the absence of drug costs
(£18561 for aspirin and £20475 for no treatment). Note that
aspirin and no treatment were compared with dabigatran
without a second-line treatment (7.99 QALYs and £19961
management costs). In the population initiating treatment at
Table 1 Major cost parameters (2010 prices in £)
Drug costs Per day Source
Dabigatran etexilate 2.52 24
Warfarin (5 mg) 0.04 24
Aspirin (162.5 mg) 0.09 24
Monitoring costs Per annum Source
International normalised ratio monitoring 414.90 25
Event costs Per acute event Source
Ischaemic stroke, fatal 3059 27
Ischaemic stroke, independent 3401 27
Ischaemic stroke, moderate disability 17743 27
Ischaemic stroke, totally dependent 24234 27
Systemic embolism, fatal 400 Assumption
Systemic embolism, non-fatal 2373 26
Transient ischaemic attack 1064 26
Intracranial haemorrhage or haemorrhagic
stroke, fatal
3059 27
Intracranial haemorrhage or haemorrhagic
stroke, independent
3401 27
Intracranial haemorrhage or haemorrhagic
stroke, moderate disability
17743 27
Intracranial haemorrhage or haemorrhagic
stroke, totally dependent
24234 27
Extracranial haemorrhage, fatal 1852 26
Extracranial haemorrhage (gastrointestinal),
non-fatal
1594 26
Extracranial haemorrhage (non-gastrointestinal),
non-fatal
2109 26
Minor bleed 84 25
Acute myocardial infarction 2956 26
Follow-up costs Per Quarter Source
Independent with stroke history 331 27
Moderate disability with stroke history 2868 27
Dependent disability with stroke history 6089 27
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Heart rhythm disordersage 80 or above, total QALYs and costs were reduced (4.11
QALYs and £10424 management costs for dabigatran vs 4.04
QALYs and £9919 management costs for warfarin). Costs had
a similar breakdown of drug, acute event and follow-up costs as
the population initiating treatment before age 80.
In the population initiating treatment before age 80, the
incremental cost-effectiveness ratio (ICER) was £4831/QALY
gained, while in the population initiating treatment at 80 the
ICER was £7090/QALY gained. In the scenario analyses which
compared initiating dabigatran before age 80 with treatment
with aspirin, the ICER was found to be £3457/QALY gained,
while dabigatran dominated receiving no thrombophylaxis (ie,
more effective and less costly).
Deterministic sensitivity analyses
Deterministic sensitivity analyses for the base-case model
showed cost-effectiveness of dabigatran versus warfarin was
robust to variations in the majority of parameters, including
changes in underlying clinical event rates, costs, utilities and
discounting. Key parameters that affected the cost-effectiveness
were the degree of INR control attained by patients on warfarin,
the RR and overall rates of IS, ICH and HS for dabigatran versus
warfarin, the cost of long-term follow-up care for patients with
disability, and time horizon analysed (ﬁgure 2). Signiﬁcant
differences in the cost of INR monitoring while on warfarin also
had an effect on the ICER. To reach a willingness-to-pay
threshold of £20000 and £30000/QALY gained required an
average time in therapeutic range for the whole cohort of
approximately 91% and 97% for the population starting therapy
at age <80 years, and 80% and 83% in the population starting
therapy at age $80 years, respectively.
Over a time horizon of only 10 years, the mean survival of the
modelled patient population, the ICER was £11898/QALY
gained. Using the upper limit of the 95% CI for the RR of IS,
ICH or HS for dabigatran versus warfarin increased the ICERs to
£13353, £10013 and £8420/QALY gained, respectively. Using
full RE-LY clinical results instead of age-stratiﬁed results yielded
an ICER of £4985/QALYand £13645/QALY in the <80 and $80
populations, respectively.
Probabilistic sensitivity analyses
PSA simulation of dabigatran versus warfarin treatment for
patients initiating treatment at age 80 or above showed that
dabigatran increased QALYs in all simulation runs, with most,
but not all, showing increased costs. Similarly, dabigatran
resulted in an increase in QALYs in simulations versus aspirin or
no treatment when patients initiated treatment before age 80,
and in 82% of simulations versus warfarin when patients initi-
ated treatment at age 80 or above. Figure 3 shows the cost-
effectiveness acceptability curves for each scenario analysed.
These curves show the fraction of simulations that resulted in
cost-effectiveness below a speciﬁc willingness-to-pay (WTP)
threshold. For example, the probability that dabigatran is cost
effective for patients under the age of 80 years at the commonly
cited WTP threshold of £20000/QALY gained was 98% against
warfarin, and 100% against aspirin and no treatment. In
patients initiating treatment at age 80, the probability of cost-
effectiveness versus warfarin was 63% at the same WTP
threshold.
DISCUSSION
This economic evaluation estimated the cost-effectiveness of
dabigatran compared with warfarin, aspirin and no treatment
for prevention of stroke and SE in patients with AF. The
modelled evaluation estimated that use of dabigatran was likely
to be cost effective in all comparisons and analyses conducted.
That is, for all comparisons, the ICERs for dabigatran were well
below the benchmark WTP threshold of £20000/QALY gained.
The low ICERs for patients receiving dabigatran reﬂect the
signiﬁcant reduction in catastrophic events (IS, ICH and HS)
and the substantial savings that were achieved through the
reduction in long-term disability as a consequence. Cost effec-
tiveness for dabigatran treatment versus warfarin was demon-
strated for patients initiating treatment at age 80 years despite
Figure 2 Deterministic sensitivity
analysis showing the effect of varying
key parameters over a plausible range
on incremental cost-effectiveness ratios
(ICERs) of dabigatran initiated prior to
age 80 versus warfarin. The black bar
shows the results with the ﬁrst
parameter variation indicated in the
parentheses (eg, the upper CI limit for
RR of ischaemic stroke with dabigatran
yields an ICER of £13353/quality-
adjusted life year (QALY)), while the
grey bar shows the results using the
second variation in the parentheses (eg,
the lower CI limit for RR of ischaemic
stroke with dabigatran yields an ICER of
£2124/QALY). The base case ICER is
£4831/QALY.
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Heart rhythm disorderssimilar clinical beneﬁt for warfarin and dabigatran treatment in
terms of IS. In this population, which receives only the 110 mg
twice daily dose of dabigatran, cost-effectiveness is driven
speciﬁcally by the reduction in ICH and HS and associated
reductions in mortality and disability. Deterministic and prob-
abilistic sensitivity analyses showed that these ICERs were
robust to uncertainty and variability in the model parameters. It
was demonstrated that average population warfarin control
would need to be raised to levels not observed in routine practice
for £20000/QALY gained to be exceeded. These consistent cost-
effectiveness results are in line with the improved efﬁcacy and
safety outcomes demonstrated in RE-LY.
These results are also consistent with analyses in the US
29 30
and Canadian settings,
16 though, using a higher US dabigatran
price, Shah and Gage found low risk subpopulations in which
dabigatran was less cost effective. None of the prior analyses
presented cost-effectiveness results versus remaining untreated.
LIMITATIONS
As with any economic model, results rest on important
assumptions. The key modelling assumption is that of
continued beneﬁt with ongoing anticoagulation treatment. The
decision to anticoagulate patients with AF should be life long;
therefore, it was appropriate to model costs and outcomes over
the lifetime without arbitrarily truncating the model time
horizon, especially as post-stroke disability continues over
patients’ remaining life. To be conservative (given the higher
discontinuation rate with dabigatran versus warfarin), the
model included clinical event risks based on the intent-to-treat
population, while also explicitly including discontinuation of
treatment.
A major driver in the model is cost of long-term disability
management. As systematic follow-up of patients in RE-LY
suffering an event was limited to 3e6 months, there were
limited data available. However, it was possible to stratify stroke
outcomes by patient-level data (mRS), and thereby, assign
different cost estimates for different disability levels. This
should have resulted in more accurate estimates of total costs
than assigning overall stroke follow-up costs.
31
This model and evaluation offer a number of strengths.
Foremost is the use of clinical parameters estimated directly
from individual patient-level data in the RE-LY study. Second,
the main comparator, warfarin as studied in the RE-LY trial, can
be considered as conservative because the INR control observed
in routine UK practice is likely to be inferior in comparison.
Third, the model allowed the approved stratiﬁcation of the two
dabigatran doses to be reﬂected in the correct populations.
Fourth, it provided the ﬂexibility to investigate the cost effec-
tiveness of dabigatran compared with other treatment strategies
provided to UK patients. Finally, the model has been populated
with UK-relevant data, and the stroke risk proﬁles of the patient
populations are representative of those that would be expected
in UK patients.
CONCLUSION
In conclusion, treatment with dabigatran reduced the risk of
stroke and intracranial haemorrhage compared with warfarin,
aspirin and those patients remaining untreated. These clinical
beneﬁts offset a substantial portion of the additional drug cost
associated with dabigatran, yielding favourable cost-effective-
ness ratios well below standard WTP thresholds. Overall, this
economic evaluation supports the use of dabigatran as a cost-
effective ﬁrst-line treatment for the prevention of stroke and SE
in eligible UK patients with AF.
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Figure 3 Cost-effectiveness acceptability curves showing the fraction
of probability sensitivity analysis simulations that yield incremental
cost-effectiveness ratios below a speciﬁed threshold for dabigatran
initiated prior to age 80 versus warfarin (solid black), aspirin (dashed
grey), and no treatment (dashed black). Dabigatran initiated after age
80 is also compared with warfarin (solid grey). QALY, quality-adjusted
life year.
Key messages
Using data from the Randomised Evaluation of Long-Term Anti-
coagulation Therapy (RE-LY) trial, and relevant UK costs and
resource use, this analysis suggests that the use of dabigatran as
a ﬁrst-line treatment for the prevention of stroke and systemic
embolism is likely to be cost-effective in eligible UK patients with
atrial ﬁbrillation compared with well controlled warfarin, and
‘dominant’ (less costly and more effective) compared with no
therapy.
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